首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1558754篇
  免费   133960篇
  国内免费   20290篇
医药卫生   1713004篇
  2021年   19559篇
  2020年   13425篇
  2019年   16358篇
  2018年   21081篇
  2017年   17377篇
  2016年   19202篇
  2015年   24023篇
  2014年   32204篇
  2013年   41158篇
  2012年   53115篇
  2011年   57470篇
  2010年   35713篇
  2009年   32932篇
  2008年   48563篇
  2007年   51038篇
  2006年   51705篇
  2005年   50480篇
  2004年   44925篇
  2003年   43094篇
  2002年   40116篇
  2001年   71207篇
  2000年   73232篇
  1999年   62342篇
  1998年   20190篇
  1997年   18527篇
  1996年   18679篇
  1995年   18696篇
  1994年   17222篇
  1993年   15583篇
  1992年   48998篇
  1991年   47435篇
  1990年   45366篇
  1989年   43005篇
  1988年   39759篇
  1987年   39004篇
  1986年   36570篇
  1985年   35241篇
  1984年   26718篇
  1983年   22373篇
  1982年   13999篇
  1981年   12574篇
  1979年   23706篇
  1978年   17133篇
  1977年   14425篇
  1976年   13217篇
  1975年   13767篇
  1974年   16170篇
  1973年   15465篇
  1972年   14230篇
  1971年   13093篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
62.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
63.
Metabolism describes the series of chemical reactions that are concerned with the provision of energy to biological systems. They may be divided into reactions involved in energy yield (catabolism: demand exceeds supply), and energy storage (anabolism: supply exceeds demand). Regulation of these pathways is critical for homeostasis, and derangements in metabolism are seen in a wide variety of pathological processes. Understanding metabolism is key to the treatment of many diseases, notably diabetes, as well as underpinning clinical nutritional support.  相似文献   
64.
65.
66.
67.
68.
69.
70.
Henna, derived from a combination of natural leaves and coloring additives, is a common decorative dye traditionally used in many Islamic religious celebrations. Para‐phenylenediamine (PPD), a major component of black henna tattoo, is a strong sensitizer and common allergen. We report a case of severe connubial allergic contact dermatitis after black henna heterotransfer in a girl.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号